Ohad Cohen, Switzerland
Medtronic International Trading Sarl Medical AffairsPresenter of 6 Presentations
Closing and Q&A
COST-EFFECTIVENESS ANALYSIS OF THE MINIMEDTM 780G SYSTEM VERSUS MULTIPLE DAILY INJECTIONS WITH INTERMITTENTLY SCANNED CONTINUOUS GLUCOSE MONITORING IN INDIVIDUALS WITH TYPE 1 DIABETES IN AUSTRIA
Abstract
Background and Aims
This study assessed the long‐term cost‐effectiveness of the MiniMedTM 780G system versus Multiple Daily Injections (MDI) with intermittently scanned continuous glucose monitoring (isCGM) in people with type 1 diabetes (T1D) in Austria.
Methods
The IQVIA‐CORE‐Diabetes‐Model was used to perform cost‐effectiveness analysis over simulated patient lifetime. Clinical data were derived from the MiniMedTM 780G system pivotal clinical study1,2, the isCGM prospective observational real-world cohort study (FUTURE)3, and the European severe hypoglycaemia event rates (SHE) study4. For the former, assumptions for HbA1c reduction, given an 8.0% (63.9 mmol/mol) level at baseline, were 0.8% with MiniMedTM 780G system and 0% with isCGM. For the latter, assumptions requiring medical assistance for SH were 0 vs 0.25 per patient-year for the MiniMedTM 780G system versus isCGM. Cost data, expressed in 2020 Euros, were obtained from published sources and represented Austrian reimbursement prices. Societal perspective was used.
Results
The MiniMedTM 780G system was associated with a quality‐adjusted life‐year (QALY) gain of 2.09 but higher overall costs versus MDI+isCGM, leading to an incremental cost‐effectiveness ratio (ICER) of €24475 per QALY-gained. MiniMedTM 780G system use resulted in a lower cumulative incidence of diabetes‐related complications. Higher acquisition costs were partially offset by reduced complications costs. Extensive sensitivity analysis on key drivers confirmed the robustness of results.
Conclusions
Compared to MDI±isCGM, MiniMed™ 780G therapy was associated with clinical benefits and QALY improvements in patients with T1D in Austria. At a willingness-to-pay threshold of €28000 per QALY-gained, the system likely represents a cost-effective treatment option.
The MiniMed™ 780G System : Real-Word Evidence from the First 4,000 Users
Opportunities and challenges of a remote onboarding
REAL-WORLD OUTCOMES OF THE FIRST 1’000 USERS OF THE MINIMEDTM 780G SYSTEM
Abstract
Background and Aims
The MiniMedTM 780G system clinical trials demonstrated improved glycemic control of >70% of time spent in target glucose range (70-180 mg/dL, TIR) and HbA1c or Glucose Management Indicator (GMI) of <7%.1,2 Following introduction of the system in Europe, in October 2020, real-world glycemic control outcomes were evaluated.
Methods
MiniMed™ 780G system data from countries having ≥50 users were uploaded voluntarily to CareLinkTM Personal software from 05October2020- 11December2020 by individuals providing consent, and analyzed. Mean sensor glucose (SG), GMI, and percentage of time spent across SG ranges and in closed loop (automated basal, at minimum) were determined for users having ≥10 days of SG data after initiating MiniMed™ 780G automated basal and correction boluses.
Results
Individuals (N=1033) had a TIR of 76.8±9.1% and SG of 142.6±14.3 mg/dL (7.9 mmol/L), corresponding to a GMI of 6.7±0.3% (Figure). Time spent at <70 mg/dL and <54 mg/dL was 2.7±2.3% and 0.6±0.9%, respectively, while time spent at >180 mg/dL was 20.4±9.3%. The percentage of users achieving a TIR >70% and a GMI <7.0% was 80.2% and 82.4%, respectively. Time below ranges of <1% (for <54 mg/dL) and <4% (for <70 mg/dL) were achieved by 74.8% of users, and while in closed loop 92.7±10.8% of the time.
Conclusions
In this first analysis of real-world MiniMedTM 780G system data, most users achieved internationally recommended goals of glycemic control for TIR, TBR3 , and GMI. These results are similar to those observed in the MiniMedTM 780G system clinical trials, supporting real-world reproducibility and providing evidence to the robustness of the algorithm.
Introduction of speakers and agenda
Moderator of 2 Sessions
Successfully Initiating MiniMed(TM) 780G System: a Structured 10-Days Protocol - Industry Symposium Supported by Medtronic International Trading Sàrl
Session description - The MiniMed(TM) 780G system contains an advanced hybrid closed loop (AHCL) algorithm which includes automatic basal insulin delivery and automatic correction bolus delivery with the goal of improving clinical outcomes, while reducing demands on users and caretakers. Prof. Goran Petrovski will share the experience from Sidra Medicine, Qatar, in initiating individuals from MDI therapy directly to the MiniMed(TM) 780G system, following a structured 10-days protocol. The initiation protocol will be described, and its implementation will be exemplified by cases from the clinical practice. The participants will be able to comment and share their experiences and recommendation.
Remote Onboarding of Advanced Technology - Industry Symposium Supported by Medtronic
Session description - A workshop on the development, experience and clinical outcomes of a Remote Onboarding Programme on Medtronic devices. The coronavirus disease (COVID-19) pandemic has forced a change towards telemedicine-based healthcare support for people with diabetes. A structured Remote Onboarding Programme for Type 1 diabetes patients to the MiniMed™ insulin pump systems therapy using video-conferencing platforms instead of face-to-face training sessions was developed. The Medtronic Remote Onboarding Programme modified existing content used during face-to-face technical trainings to a more agile and suitable format for virtual use by introducing new tools, defining processes, and fulfilling data privacy requirements and regulations. This programme was created by a task force assembled from Medtronic technical consultants (TCs), medical and clinical personnel, patient-experience experts, as well as data privacy and legal representatives. Aims of the workshop is to present both these tools in an interactive way and the first results of a pioneer centre, the University Federico II in Naples, that started to use these tools last June 2020 to train remotely their Type 1 diabetes patients candidate to an Hybrid Closed Loop system.